Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think this sounds right.
Around the time the last F-6 was released. Avita medical issued two PR statements. First they issued this pr https://www.asx.com.au/asxpdf/20120220/pdf/424g0jwst3t2sc.pdf
saying they intended to get on OTC using Mellon bank.
Second they issued this PR https://www.asx.com.au/asxpdf/20120309/pdf/424xq1yf5vhrhj.pdf
saying they were successful in doing so.
So either this is a related to nasdaq uplisting requirements or is related to the continuation of the OTC adr requirements as it relates to the Mellon bank. I expect we hear something from the Company about this soon.
Okay yeah you must be correct. Thanks for the reply. Looking into it avita medical has only released one other F-6 form that was back in 2012 for the same bank Mellon. https://seekingalpha.com/filing/524445
In this previous F-6 they also had the same proposed maximum price per unit of $5. so that is interesting. Perhaps it is a requirement needed by the bank. like perhaps all 50million shares registered to the ADR have been held and they need more registered shares. I dont know what to make of the $5 dollar unit price, but because it is in both the 2012 and 2019 f-6 statements makes me think it is not relevant to the security price per share and is only relevant to the fee associated with registering the shares.
Getting this without any PR information explaining it from the Company is really bad PR imo. From the face value of my two cents it looks like the Company is adding 200million shares to its outstanding shares, while this seems to say that the for this issuance the maximum value of proceeds allowed is 10million at $5 per share so that means 2million shares of dilution is to be expected in the short term.
Having this drop without any news about Nasdaq uplist is really bad pr imo. I am curious about what everyone else thinks about this, but i am kinda wishing I sold today..
Interesting that it took this long for Avita medical to make a official PR about this. I reported on this blog about these results 9/5/19 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150943744
I am not complaining, this PR is really a well timed, especially if it is closely followed up with an announcement about the NASDAQ uplist.
Both are ADRs avmxy has 20 times less shares on the market. while AVMXF has the same number of share as AVH and therefore has 20 times more share than AVMXY
Well the timing would sure be perfect if the company could announce NASDAQ uplisting at the conference. Fingers crossed.
The mythical NASDAQ uplisting, so close we can taste it. it will be a exciting few days once the news hits.
New China Acne Scar Clinical Study Results Published.
Nine days ago there was a publications of clinical study conducted in china using 78 patients with acne scars. Recell was used in comparison with current methods, recell was found to significantly improve healing time by about 40% and reduced postoperative complications to zero, with improved patient satisfaction.
Link
I cant wait until recell starts getting regularly used for scar and aesthetic dermatology treatments. $$$
The recell unit is already approved as a platform for applying autologous cells. It is not a far stretch to use the same platform to apply cells in combination with 3d printed skin/tissue constructs. But I am not a expert so I don't know, but something tells me that there might be a market there for the Recell platform and if there is I am willing to bet that Avita medical and Dr Wood are looking for ways to leverage the circumstances.
Just a reminder for the old timers and something new for the recent investors. In March the founder of Avita Medical Fiona Wood gave a lecture about some of the work she is involved in currently. Here is a little quote from Dr. Wood that I want to share.
I think these results were probably part of the data used by the FDA for PMA, but i am not sure.
Results from a MAJOR ReCell clinical trial just posted and have been accepted and published by the U.S. Federal Government. The first such clinical trial for Avita Medical to meet this completion milestone with publication of data, more are sure to follow. Looks like this was published today, I've been waiting for these to post. Looks great, pretty much for all measures recell is better than the control, with only minor exceptions that can mostly be rationalized by the technique itself rather than the performance of the recell system as a whole.
Here is the link
Working LINK to Patent Extension Response and ongoing discussion with the USPTO about how the USPTO is in discussion with FDA. All things are on point, the letter actually makes it seem like the inspector at the USPTO already thinks everything is in-order for it to occur.
Share price requirement should be specific the the ADR of question, which is AVMXY, because that would be the only listing looking for uplisting to nasdaq. All other associated listing price per share value like AVH on ASX would not be relevant to the nasdaq uplisting. I do not have any specific references for this, but I know that other companies have been in similar situations but I cant think of their names right now. Anyways, IMO the nasdaq uplisting is imminent(maybe as soon as monday or as late as july) and i think it has already been partially accounted for in the current SP of AVMXY.
AVMXY has met all the requirements for nasdaq uplisting for the Capital market as well as the Global Capital market. So it could happen any time, literary just seems like they could apply and proceed with uplisting at any time. For all we know it is already in the works and we could wake up any day with AVMXY trading on nasdaq.
Patent extension of upto 5 years is on the near horizon. In february USPTO responded to Avita Medicals request for patent extension under the rules of extension for time lost during regulatory approval. They notified Avita Medical of the request to the FDA for information relating this request.
Link to USPTO response and request for confirmation from FDA
Link to FDA info on their role in eligible patent extensions.
Looks like we will soon see the patents extended ~5 years to ~2027
The Cowen and Company presentation is huge. Some new things I noticed with this presentation.
More than 8000 patients treated instead of 7000 thousand on page 10.
Key milestones for 2019 include commencement of at least 3 clinical trials, with one traumatic wound trial and multiple vitiligo clinical trials.
Couple other things that I liked seeing was the BARDA procurement and NASDAQ uplisting are still on for this year. Also the plan to partner and move to clinical trials and commercialization with chronic wounds is still planned as well. This last one was not mentioned in the 2019 milestones so I am not sure about 2019, but the chronic wound market is a important one for recell so it will be good to see them partner with a big boy and move into the market.
IMO Today the short sellers are going to be forced to cover and I am guessing we are going to see this thing up to around ~$2.34 today. This move is going to really set us up nice going into april and going into the next financial report at the end of april.
Wow this is fantastic. So this is probably the first time for avh to be on a important index as part of the asx S&P DJI all ordinaries. Awesome, bet this opens us up to more people seeing this stock and more people and corporations wanting to invest.
Hope the cadence of these PR drops continues this is great.
GLTA. some interesting times
StLXer is out and active again spreading deception and manipulation. Also looks like MCAP and PUMA have been keeping the spread small and being heavy on the sell orders today. Also along with these things we had a pretty big jump in avg short selling in the last report from 1/31/ to 2/15, the price was around this level at the time, so the shorts want to see the price decrease from here.
Makes me think we are seeing the shorts trying to push the stock down and even resorting to using the StLXer account to drive price manipulation. Despite this there have been active buying occuring, people are buying large chunks taking advantage of MCAP and PUMA riding the sell orders heavy with a short spread.
IMO Overall should be interesting to see where this goes. IMO If StLXer has his way the price will average lower until early-mid april before the rise and huge jump that will happen on april 31st with q1 earnings report. Or IMO if StLXer does not get his way the price will stay flat and even rise gradually forcing the shorts to cover at some point in the next week or two and into mid april.
That is a good thing IMHO we dont want the stock to move much, volatility doesn't really help the honest long investors and only helps the shorts, the day traders, and the market makers. Between big news events and big reporting events we want to see stability in sideways movement with slow and steady growth.
Avita Medical Partners with M3 subsidiary COSMOTEC to market and sell Recell units in Japan. !!! great news and timing for this news.
Link
Also the other filing is interesting as well, we learned that some mysterious open packages in EU resulted in a pause in EU sales to be started again 4th quarter at the latest. Interesting but not too concerning, seems like it wont effect the US sales at all and wont really effect the bottom line because of the importance of US sales now. Still it is kinda weird.
M3 inc collaboration is huge!
The January US Army purchase was not the first. I don't know how I missed this but in October last year a couple weeks after FDA approval the DOD - US ARMY purchased $39000 worth of ReCell Units, So assuming a fixed price of $7500 per unit, that equates to about 5 units. This first order went to Fort Sam Huston the same place that the second order went, but the first order had originated from a different contact than the second order did. It looks like the first order went to a blood laboratory at Sam Huston, and the second order went to medical center at Fort Sam Huston.
Looks like Sam Huston is set up to be the first regular commercial purchaser of ReCell units from the DOD. It is great news, IMO we can expect the next order will be probably be at least 10 times the first order, with regular purchases to follow in suit
US Army requests quote from Avita Medical for 5 ReCell Units. Link
So last month looks like the US Army sent out a opportunity for a quote from Avita Medical for 5 ReCell units. Even though this is just 5 units it is a big deal. The amount of units requested by the US Army is enough to ensure they could probably have enough units to treat one severly burned patient. Or a few patients without severe burns. To me this says they are going to test the product out as it is in its Pre-market Approved form to make sure it is the same as it was when the US Army conducted trials using the ReCell units before pre market approval. Seems to me like this is a precursor for the US Army to maintain a stock pile of these units for treatment in the United States for veterans and military personal, in addition to perhaps keeping them stock piled at US Army bases around the world for general use.
Predicting specifics like that is pretty tricky. If i were to venture a guess Id say in a year $5 is pretty conservative to expect lots of support at that price. While in a year maybe a high will be in the 15-20$ range and I would expect year over year growth for the foreseeable future. Its a good stock to hold that I am pretty sure of.
Yeah looks like PUMA has pulled off the sell for now, hopefully it stays that way, hopefully we dont see major price swings and just a steady gradual rise. So far the market has responded very positively to this news of ~1,000,000 USD in sales this quarter, which is the best quarter this company has ever had as far as sales goes. Very positive indeed.
FYI the OTC markets website shows the spread with the MM tags
https://www.otcmarkets.com/stock/AVMXY/overview
PUMA market maker is on the sell for the first time since I can remember for this stock. Seems like PUMA is probably bearish on the upcoming financial report, and setting up to short sell the heck out of it before hand and upon release. I think we might see PUMA get burned come Thursday, I have a good feeling about the financial report and the pre-market launch sales numbers. If we see sales numbers of around 7-10 million USD I think PUMA will probably get burned from their selling today and tomorrow (if they stay on the sell tomorrow) and I expect to see the stock price back up to 1.90 or so by Friday, but if we see sales numbers of only 1-3 million USD I think PUMA will short sell it down to ~1.40 or so.
GLTA should be a interesting week either way. Also this is a solid stock and I do not even worry about these near term price fluctuations I wont be selling for a year or so anyways. This stock has tremendous upside potential over the next year or so and going forward. Holding long. If we have solid pre-market sales numbers this week, with guidance for the following quarter, we could get pushed up to greater than $2.00 by next week and be in a position for NASDAQ up-listing the following week.
Seeing that we have >40 mill in the bank with a strong likelihood of becoming profitable this year. how about never..
Intraday short volumes are unreliable, and making meaning out of them is looking for trouble, best just to wait for the two week short reports IMO.
I think the lag between training hospitals and them being regular customers has to do with the the hospital/administration going through their processes of switching treatment or using a new device. Each hospital has their own set of requirements that a device must go through, such as evaluation at their own hospital with their own staff, before they fully switch over. The company has said that many of the hospitals are expediting that processes, but it is known that this process can take a few months to go through.
User from hot copper has good review of the just released Corporate Presentation: User ydqcau says
Scholarly article on US clinical results that included 3rd degree burns is out.
Published 12 days ago is a scholarly article showing the effectiveness of Recell vs control treatments on mixed burns that included full thickness burns, or 3rd degree burns. This is great news, the results are positive, with better healing on wound sites and also less skin needed. Further entrenching Recell tech in its market superiority for its overall effectiveness as a burn general treatment, that includes full thickness burns.
Here is the link.
Also released earlier this year in china is a scholarly article showing the effectiveness of using Recell in plastic surgery for increased wound healing. This is great to see that Recell is finding further diversity use cases in china, and one that I did not really anticipate. Use of Recell for general surgical practices such as plastic surgery wound healing is a huge market.
Here is the link
Things are looking good for the new year. Excited to see sales numbers coming out soon !
GLTA
You are missing logic again in your argument. The loss in value of the company occured before the dilutive funding from the capital equity raising event which occurred on november 30th. So gotcha.. again..
The company has no debt, the company just went though $40million AUD capital raising event, which was not associated with acquisition of debt but instead it was associated with selling of shares to shareholders who wanted to buy the shares... not sure what your going for.. Maybe you dont understand what debt is or maybe you dont understand what capital raising through institutional placement of shares means. Or maybe you are just trying to make crap up. Either way you are pretty far off the mark thinking the company has debt or that it acquired debt.. Check out Page 6 of the last Corporate Presentation December 2018. Or check out the last quarterly/yearly financial report, zero debt.
Nice argument, you really have me convinced now. Also StL claim about loads of debt is just loads of bull crap, the company has zero debt.
GLTA upsides are coming soon.
just another bad post by StLXer.... Although StL's sentences are mostly readable in his last post, so there is some improvement..
All the evidence points to a great company and CEO.
Just out Avita medical is top of pm360s top innovative companies list for 2018.